by Francisca Peixoto | Jun 14, 2023 | Uncategorized
Our portfolio company Ochre Bio’s CEO Jack O’Meara spoke on The Healthtech Podcast, hosted by Dr. James Somauroo, where he discussed: How and why we utilise human livers outside the body for developing new liver medicines Why the FDA no longer mandates...
by Francisca Peixoto | Jun 7, 2023 | Uncategorized
Our portfolio company Macomics’ co-founder Luca Cassetta did an interview at Drug Discovery World with Diana Spencer, talking about #macrophages, #TechTransfer, #fundraising strategy and other learnings from co-founding Macomics. Macomics is exploiting the...
by Francisca Peixoto | Jun 1, 2023 | Uncategorized
“Biotech is the ultimate impact investment”, we could not agree more. Great write up from Financial Times on private investor motivation to invest in biotech. Its difficult to find investment areas with more obvious, tangible and measurable benefits to...
by Francisca Peixoto | May 5, 2023 | Uncategorized
“The biology is complex, but not intractable”, great review by Nature Portfolio on the status and future of drugging RNA. Phenotypic screening and advanced computation have been used to find selective RNA binders. If the tools and biology can be leveraged...
by Francisca Peixoto | Mar 23, 2023 | Uncategorized
Our portfolio company Macomics announces that it has entered into a worldwide drug discovery collaboration agreement with Ono Pharmaceutical (a leader in immuno-oncology) to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in...
by Francisca Peixoto | Jan 17, 2023 | Uncategorized
Our portfolio company Spiral Therapeutics announces the completion of $8.25M in new financing, with proceeds that will fund the continuing development of their lead candidate, SPT-2101, for the treatment of inner ear inflammation. SPT-2101 is a sustained-release...
